Cerenia
maropitant
Marketing authorisation holder: Zoetis Belgium SA
Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIUM
Manufacturer responsible for batch release: FAREVA AMBOISE
Zone Industrielle,
29 route des Industries 37530 Pocé-sur-Cisse FRANCE
Cerenia 16 mg tablets for dogs Cerenia 24 mg tablets for dogs Cerenia 60 mg tablets for dogs Cerenia 160 mg tablets for dogs
maropitant
Each tablet contains 16 mg, 24 mg, 60 mg or 160 mg maropitant as maropitant citrate monohydrate. The tablets also contain Sunset Yellow (E110) as a colourant.
The tablets are pale orange and have a score line allowing the tablet to be halved, with the letters “MPT” and figures denoting the quantity of maropitant on one side, the reverse side is blank.
For the prevention of nausea induced by chemotherapy.
For the prevention of vomiting induced by motion sickness.
For the prevention and treatment of vomiting, in conjunction with Cerenia solution for injection
and in combination with other supportive measures.
None.
Administering Cerenia on a completely empty stomach may cause your dog to vomit. Giving your dog a light meal or snack before administering the tablet could help preventing this effect. Prolonged fasting before administration should be avoided.
Cerenia is not a sedative and some motion sick dogs may show nausea-like signs during travel such as salivation and lethargy. These signs are temporary and should resolve when the journey ends.
Lethargy has been reported in very rare cases, based on post-marketing safety experience. The frequency of adverse reactions is defined using the following convention:
− very common (more than 1 in 10 animals treated displaying adverse reaction(s))
− common (more than 1 but less than 10 animals in 100 animals treated)
− uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
− rare (more than 1 but less than 10 animals in 10,000 animals treated)
− very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.
Dogs.
For oral use.
To treat and/or prevent vomiting except motion sickness, Cerenia tablets should be administered once daily, at a dose of 2 mg maropitant per kg bodyweight, using the number of tablets given in the table below. Tablets are breakable along the score line on the tablet.
To prevent vomiting, tablets should be given more than 1 hour in advance. The duration of the effect is approximately 24 hours and, therefore, tablets can be given the night before administration of an agent that may cause emesis (e.g. chemotherapy).
Cerenia can be used to treat or prevent vomiting either as tablets or as solution for injection administered once daily. Cerenia solution for injection may be administered for up to five days and Cerenia tablets for up to fourteen days.
Prevention of nausea induced by chemotherapy Treatment and prevention of vomiting (except motion sickness) | |||
Dog body weight (kg) | Number of tablets | ||
16 mg | 24 mg | 60 mg | |
3.0–4.0* | ½ | ||
4.1–8.0 | 1 | ||
8.1–12.0 | 1 | ||
12.1–24.0 | 2 | ||
24.1–30.0 | 1 | ||
30.1–60.0 | 2 | ||
To prevent vomiting induced by motion sickness, Cerenia tablets should be administered once daily, at a dose of 8 mg maropitant per kg bodyweight, using the numbers of tablets given in the table below. Tablets are breakable along the score line on the tablet.
Tablets should be administered at least one hour before starting the journey. The anti-emetic effect persists for at least 12 hours, which for convenience may allow administration the night before early morning travel. Treatment may be repeated for a maximum of two consecutive days.
In some individual dogs and when repeating the treatment, lower doses than recommended might be sufficient.
Prevention of motion sickness only | ||||
Dog body weight (kg) | Number of tablets | |||
16 mg | 24 mg | 60 mg | 160 mg | |
1.0-1.5 | ½ | |||
1.6–2.0 | 1 | |||
2.1–3.0 | 1 | |||
3.1–4.0 | 2 | |||
4.1–6.0 | 2 | |||
6.1–7.5 | 1 | |||
7.6–10.0 | ½ | |||
10.1–15.0 | 2 | |||
15.1–20.0 | 1 | |||
20.1–30.0 | 1½ | |||
30.1–40.0 | 2 | |||
40.1–60.0 | 3 | |||
To remove a tablet from the blister the following sequence should be carried out;
Firstly, fold or cut along the perforation between each tablet as shown by the scissor symbol
Find the pull-back notch (or cut) as shown by the arrow symbol .
Holding one side of the cut firmly, pull the other side towards the centre of the blister until the tablet is visible.
Remove tablet from blister and administer as instructed.
Note: No attempt should be made to remove the tablet by pushing it through the blister backing as this will damage both the tablet and blister.
For motion sickness a light meal or snack before dosing is recommended, prolonged fasting before administration should be avoided. Cerenia tablets should not be administered wrapped or encapsulated in food as this may delay dissolution of the tablet and consequently the onset of the effect.
Dogs should be carefully observed following administration to ensure that each tablet is swallowed.
Not applicable.
Keep out of the sight and reach of children.
This veterinary medicinal product does not require any special storage conditions.
Half-tablets should be stored for a maximum of two days after removal from the blister. Half-tablets should be returned to the opened blister and kept within the cardboard outer.
Do not use this veterinary medicinal product after the expiry date which is stated on the blister after EXP.
Special warnings for each target species:
Vomiting can be associated with serious, severely debilitating conditions and the cause should be investigated. Products such as Cerenia should be used in conjunction with other supportive measures such as dietary control and fluid replacement therapy, as recommended by your veterinary surgeon. The safety of maropitant during treatment beyond 5 days has not been explored in the target population (i.e. young dogs suffering from viral enteritis). In case treatment for a longer period than 5 days is regarded as necessary, careful monitoring of potential adverse events should be implemented.
Maropitant is metabolised in the liver and therefore should be used with caution in dogs with liver disease. As maropitant is accumulated in the body during a 14-day treatment period due to metabolic saturation, careful monitoring of liver function should be implemented during long term treatment.
Special precautions for use in animals:
The safety of Cerenia has not been established in dogs less than 16 weeks of age for the 8 mg/kg dose (motion sickness), and in dogs less than 8 weeks of age for the 2 mg/kg dose (vomiting) as well as in pregnant or lactating bitches. The responsible veterinarian should make a benefit-risk assessment before using Cerenia in dogs under 8 or 16 weeks of age, respectively, or in pregnant or lactating bitches.
Clinical signs including vomiting on first administration, excess salivation and watery faeces have been observed when the product has been overdosed in excess of 20 mg/kg.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
People with known hypersensitivity to maropitant should administer the veterinary medicinal product with caution.
Wash hands after use. In case of accidental ingestion seek medical advice immediately and show the package leaflet or the label to the physician.
Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.
Cerenia tablets are supplied in blister packs with four tablets per pack. Not all pack sizes may be marketed.
Marketing authorisation holder: Zoetis Belgium SA
Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIUM
Manufacturer responsible for batch release: FAREVA AMBOISE
Zone Industrielle,
29 route des Industries 37530 Pocé-sur-Cisse FRANCE
or
Zoetis Manufacturing & Research Spain, S.L. Ctra. de Camprodón, s/n°
Finca La Riba Vall de Bianya Gerona 17813 SPAIN
Cerenia 10 mg/ml solution for injection for dogs and cats maropitant
The solution for injection contains 10 mg maropitant per ml as maropitant citrate monohydrate as a clear, colourless to light yellow solution.
It also contains metacresol (as preservative).
For the treatment and prevention of nausea induced by chemotherapy.
For the prevention of vomiting except that induced by motion sickness.
For the treatment of vomiting, in combination with other supportive measures.
For the prevention of perioperative nausea and vomiting and improvement in recovery from general anaesthesia after use of the μ-opiate receptor agonist morphine.
For the prevention of vomiting and the reduction of nausea, except that induced by motion sickness.
For the treatment of vomiting, in combination with other supportive measures.
None.
Pain at injection site may occur when injected subcutaneously.
In cats, moderate to severe response to injection is very commonly observed (in approximately one third of cats).
Anaphylactic type reactions (allergic oedema, urticaria, erythema, collapse, dyspnoea, pale mucous membranes) may occur in very rare cases.
Lethargy has been reported in very rare cases, based on post-marketing safety experience. The frequency of adverse reactions is defined using the following convention:
very common (more than 1 in 10 animals treated displaying adverse reaction(s))
common (more than 1 but less than 10 animals in 100 animals treated)
uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
rare (more than 1 but less than 10 animals in 10,000 animals treated)
very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.
Dogs and cats.
For subcutaneous or intravenous use in dogs and cats.
Cerenia solution for injection should be injected subcutaneously or intravenously, once daily, at a dose of 1 mg/kg bodyweight (1 ml/10 kg bodyweight). Treatment may be repeated for up to five consecutive days. Intravenous administration of Cerenia should be given as a single bolus without mixing the product with any other fluids.
In dogs, Cerenia solution for injection can be used to treat or prevent vomiting once daily for up to 5 days.
To prevent vomiting, Cerenia solution for injection should be administered more than 1 hour in advance. The effect duration is approximately 24 h and therefore treatment can be given the night before administration of an agent that may cause emesis e.g. chemotherapy.
Due to the frequent occurrence of transient pain during subcutaneous injection, appropriate animal restraining measures may have to be applied. Injecting the product at refrigerated temperature may reduce pain at injection.
Not applicable.
Keep out of the sight and reach of children.
This veterinary medicinal product does not require any special storage conditions.
Shelf life after first opening the vial: 60 days. Do not use this veterinary medicinal product after the expiry date which is stated on the label of the vial after EXP.
Special warnings for each target species:
Vomiting can be associated with serious, severely debilitating conditions and the cause should be investigated. Products such as Cerenia should be used in conjunction with other supportive measures such as dietary control and fluid replacement therapy, as recommended by your veterinary surgeon.
Maropitant is metabolised in the liver and therefore should be used with caution in dogs and cats with liver disease. Cerenia should be used with caution in animals suffering from or with predisposition for heart diseases.
The use of Cerenia solution for injection against vomiting due to motion sickness is not recommended. The efficacy of Cerenia in reduction of nausea in cats was demonstrated in studies using a model
(xylazine-induced nausea).
Special precautions for use in animals:
The safety of Cerenia has not been established in dogs less than 8 weeks of age, or in cats less than 16 weeks of age, and in pregnant or lactating dogs and cats. The responsible veterinarian should make a benefit-risk assessment before using Cerenia in dogs less than 8 weeks of age, or in cats less than 16 weeks of age, or in pregnant or lactating bitches and cats.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
People with known hypersensitivity to maropitant should administer the veterinary medicinal product with caution.
Wash hands after use. In case of accidental self-injection seek medical advice immediately and show the package leaflet or the label to the physician. Maropitant has been shown to be a potential eye irritant, and in the case of accidental eye exposure, flush the eyes with plenty of water and seek
medical attention.
Pregnancy and lactation:
Use only according to the benefit-risk assessment by the responsible veterinarian, because conclusive reproductive toxicity studies have not been conducted in any animal species.
Interaction with other medicinal products and other forms of interaction:
Cerenia should not be used concomitantly with Ca-channel antagonists as maropitant has affinity to Ca-channels.
Maropitant is highly bound to plasma proteins and may compete with other highly bound drugs.
Overdose (symptoms, emergency procedures, antidotes):
Apart from transient reactions at the injection site following subcutaneous administration, Cerenia solution for injection was well tolerated in dogs and young cats injected daily with up to 5 mg/kg (5 times the recommended dose) for 15 consecutive days (3-times the recommended duration of
administration). No data have been presented on overdoses in adult cats.
Incompatibilities:
Cerenia must not be mixed with other veterinary medicinal products in the same syringe as its compatibility with other products has not been tested.
Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.
Cerenia 10 mg/ml solution for injection for dogs and cats is available in 20 ml amber glass vials. Each cardboard box contains 1 vial.